Dose reduction of rituximab in clinical practice: a retrospective cohort study of rheumatoid arthritis patients in low disease activity on rituximab
Authors' conclusion
Dose reduction of RTX in clinical practice is effective for many RA patients and leads to relevant dose reduction.
Study context
- Population
- Rheumatoid arthritis (RA) patients using RTX in stable low disease activity (DAS28-CRP ≤3.5 for ≥6 consecutive months) with ≥2 DAS28-CRP measurements, clinical practice
- Exposure
- RTX dose reduction and stable dose after tapering vs full dose RTX
- Period 2n = 299
- Period 3n = 226
- Outcome
- Mean DAS28-CRP during the treatment periods
Methodological detailslinear mixed-model analysis
- Linear mixed-model analysis
Main finding
As reported in the abstract
Mean DAS28-CRP
Period 1
2.37
mean · 95% CI 2.29–2.44
Period 2
2.33
mean · 95% CI 2.25–2.40
Period 3
2.27
mean · 95% CI 2.18–2.35
P = 0.025
Observational data: associations, not effects.
Further findings
RTX use, median %DDD (reference 1 x 1000 mg/6 months)
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Dose reduction of rituximab in clinical practice: a retrospective cohort study of rheumatoid arthritis patients in low disease activity on rituximab. Clin Exp Rheumatol. Published 24 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →